Table of Contents Author Guidelines Submit a Manuscript
Research Article
Journal of Thyroid Research
Volume 2015, Article ID 540183, 2 pages
http://dx.doi.org/10.1155/2015/540183
Letter to the Editor

Tumor Growth Mitigating Effects of Valproic Acid in Systemic Malignancies

Private Practice, Richmond, VA 23114, USA

Received 11 May 2015; Accepted 18 May 2015

Academic Editor: Thomas J. Fahey

Copyright © 2015 Shailendra Kapoor. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Haghpanah, M. Malehmir, B. Larijani et al., “The beneficial effects of valproic acid in thyroid cancer are mediated through promoting redifferentiation and reducing stemness level: an in vitro study,” Journal of Thyroid Research, vol. 2014, Article ID 218763, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Oertl, B. Relja, J. Makarevic et al., “Altered expression of β1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid,” International Journal of Molecular Medicine, vol. 18, no. 2, pp. 347–354, 2006. View at Google Scholar · View at Scopus
  3. J. Jones, E. Juengel, A. Mickuckyte et al., “Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2342–2352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Juengel, M. Bhasin, T. Libermann et al., “Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha,” World Journal of Urology, vol. 29, no. 6, pp. 779–786, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Yang, Y. Shao, F. Yang et al., “Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity,” Archives of Medical Science, vol. 9, no. 2, pp. 323–331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Juengel, J. Makarević, I. Tsaur et al., “Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo,” PLoS ONE, vol. 8, no. 1, Article ID e53100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Zhao, W. Yang, C. Shi et al., “The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells,” Tumor Biology, vol. 32, no. 2, pp. 335–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Juengel, J. Engler, A. Mickuckyte et al., “Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro,” BJU International, vol. 105, no. 4, pp. 549–557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Yagi, S. Fushida, S. Harada et al., “Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line,” Journal of Experimental and Clinical Cancer Research, vol. 29, article 149, 2010. View at Publisher · View at Google Scholar · View at Scopus